Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Glenmark receives approval for combination of Remogliflozin Etabonate and Metformin Hydrochloride for adults with type 2 diabetes in India

Posted On: 2019-08-19 18:40:32

Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that the company has received regulatory approval to market a combination of its novel, patent protected and globally-researched sodium glucose co-transporter-2 (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) and Metformin Hydrochloride (Metformin) film coated tablets in India. The drug is indicated in the treatment of type-2 diabetes mellitus in adults. Glenmark will commercialize the product under the brand names 'Remo-M' and Remozen-M'.

Earlier in April 2019, Glenmark received regulatory approval for Remogliflozin etabonate 100 mg tablets, twice daily, aftersuccessfully completing Phase-3 clinical trials in which Remogliflozin demonstrated good efficacy and safety profile in a head-to-head comparison against Dapagliflozin. With this approval Glenmark became the first company in the world to launch the novel SGLT2 inhibitor Remogliflozin with India being the first country to get access to this innovative drug. Glenmark subsequently launched Remogliflozin in India under the brand names 'Remo' and 'Remozen'.

Glenmark has now received regulatory approval for a combination of Remogliflozin and Metformin film coated tablets. The approved dosage strengths are 100 mg of Remogliflozin combined with either 500 mg or 1,000 mg of Metformin. This combination is indicated as an adjunct to diet and exercise to improve glycemic control in type-2 diabetes mellitus patients(for full indication, it is advisable to refer the package insert).

"The approval for Remogliflozin and Metformin combination is a testament of our commitment towards revolutionizing diabetes management in India. Glenmark is a pioneer in providing access to the latest treatment options to diabetes patients in India. Earlier this year, we launched Remogliflozin with an aim to increase patients' access to SGLT2 inhibitors as this class of drugs have proven benefits for effective diabetes management. As the prevalence of diabetes continues to rise rapidly, we are pleased to offer an additional treatment option to patients. This approval for combination of Remogliflozin and Metformin will only help us get closer to our goal of providing an effective, high quality and world-class treatment option and improving access to SGLT2 inhibitors for patients in India," said Sujesh Vasudevan, President, India Formulations, Middle East and Africa at Glenmark Pharmaceuticals.

The company had launched Remogliflozin as a mono-therapy, at a breakthrough price which is over 50% lower than the existing SGLT2 inhibitors available in India. Prior to the launch of Remogliflozin, the average per day therapy cost of SGLT2 inhibitors in India was about Rs. 55.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.368.15 as compared to the previous close of Rs. 361.1. The total number of shares traded during the day was 72121 in over 1829 trades.

The stock hit an intraday high of Rs. 372.25 and intraday low of 360. The net turnover during the day was Rs. 26503702.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Motherson Sumi Systems Ltd board to consider interim dividend on Feb 28, 2020

NLC India Ltd updates on arbitration award

Lasa Supergenerics Ltd to acquire Harishree Aromatics and Chemicals Pvt Ltd

KSB Ltd launches FGD KWPK

Pee Cee Cosma Sope Ltd board declares interim dividend of Rs. 3 for FY2019-20

Sacheta Metals Ltd declares interim dividend of Rs. 0.20 for FY20

Alufluoride Ltd board declares interim dividend of Rs. 2 for 2019-20

Biocon's Insulin Manufacturing Facility in Malaysia gets 3 obsevations from U.S. FDA (PAI) inspection

PNB Housing Finance Limited's ratings downgraded to 'CRISIL AA/FAA+ / Stable'

UPL Corporation Ltd prices $400 million bonds

Dilip Buildcon Ltd executes EPC agreement with AAI for project in Gujarat

USFDA conclude inspections at Solara's Puducherry and Mangalore facility with zero 483 observations

Hind Rectifiers Limited gets 26930 Sq Mtrs land on lease from MIDC

Vesuvius India Ltd Board recommends Dividend of Rs. 8.74

M&M to sell clean energy subsidiaries to CLP India Pvt. Ltd.

Apollo Tyres Ltd board to consider preferential issue, interim dividend

Alkem's manufacturing facility at Baddi receives 2 observations from USFDA

Gulshan Polyols Ltd board declares interim dividend of Rs. 0.70

Vesuvius India Ltd Q4 PAT up at Rs. 22.70 crore

Strides Consumer announces its strategic entry into Northern India

Sahyadri Industries Ltd board declares interim dividend of Rs. 2.5 for FY2019-20

Anuh Pharma Ltd board declares interim dividend of Rs. 2.75 for FY20

PVR Ltd Opens Multiplex at Nilamber Triumph Mall in Vadodara, Gujarat

Chemcrux Enterprises Ltd Board to consider Interim Dividend on Feb 27, 2020

Muthoot Finance Ltd raises USD 550 million from International Bond Markets

TCS UK Named in The Sunday Times List of Best Big Companies to Work For 2020

USFDA reverses status of Aurobindo Pharma Ltd's general injectable formulation unit

Gujarat Alkalies and Chemicals Ltd commissions expanded capacity of Stable Bleaching Powder Plant at Dahej

Bajaj Holdings & Investment Ltd Board declares Interim Dividend of Rs. 40 for FY2019-20

Bajaj Auto Ltd Board declares Interim Dividend of Rs. 120 for FY2020

Bajaj Finserv Ltd Board declares Interim Dividend of Rs. 5 for FY20

Bajaj Finance Ltd Board declares Interim Dividend of Rs. 10 for 2019-20

Maharashtra Scooters Ltd Board declares Interim Dividend of Rs. 50

ICICI Lombard and realme Pay enter into strategic association for providing screen protection cover for realme phones

Ambuja Cements Ltd Q4 CY2019 consolidated PAT lower at Rs. 591.54 crore

ICRA revises long term rating of Indiabulls Housing Finance Limited

GMR Infrastructure Limited announces Strategic Partnership with Groupe ADP for Airports Business

Muthoot Finance Ltd announces pricing of USD 550 million 4.40% notes

UFO Moviez India Ltd board to consider interim dividend on Feb 27, 2020

Dr. Reddy's Laboratories Ltd receives EIR for Duvvada Formulations Plant

Dhanlaxmi Bank Ltd receives RBI nod for appointment of MD & CEO

Sharda Cropchem Ltd Board to consider Second Interim Dividend for FY20

Ambuja Cements Ltd Board recommends Dividend of Rs. 1.50 for CY2019

Plastiblends India Ltd board to consider interim dividend on Feb 25, 2020

Cyient Organizes Blood Donation Drive at its Hyderabad Campus

TCS Named as One of the Fortune Best Big Companies to Work For™ in 2020

India Infoline Finance Ltd raises $400 million

Ambuja Cements Limited appoints Mr. Neeraj Akhoury as new MD and CEO

Garware Technical Fibres Ltd to dispose business undertaking in USA

AstraZeneca Pharma India Ltd launches FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®)







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019